Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.

ConditionSteatosis of Liver

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age20-80

SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

About this trial

The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.

Eligibility criteria

Qualifiers

Patients will be included who are able to provide informed consent and actively participate in periodic assessments.

Disqualifiers

Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.).

Advanced neurodegenerative diseases or severe psychiatric disorders.

Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease.

Trial design

Treatments tested in this trial

Not listed

Trial groups

140 Participants

are grouped into 1 trial group

Sponsors and collaborators

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Lead sponsor

Source ClinicalTrials.gov